Literature DB >> 15542248

Analysis of MDR1 haplotypes in Parkinson's disease in a white population.

Eng-King Tan1, Marek Drozdzik, Monika Bialecka, Krystyna Honczarenko, Gabriela Klodowska-Duda, Y Y Teo, Kun Tang, Li-Peng Wong, Samuel S Chong, Chris Tan, Kenneth Yew, Yi Zhao, Caroline Gl Lee.   

Abstract

The MDR1 multidrug transporter is important in regulating environmental xenobiotics and hence may play a causative role in Parkinson's disease (PD). MDR1 haplotype comprising 2677 G > T/A and 3435 C > T may be protective against PD. Using a case control methodology, we investigated the association of MDR1 haplotypes (single nucleotide polymorphisms (SNPs) 2677 G > T/A and 3435 C > T) in a Polish PD population. Seven SNPs, extending from the promoter to exon 28 of the MDR1 gene in 158 PD patients and 139 healthy controls were evaluated. Specifically we examined the association of haplotypes containing SNPs 2677 G > T/A and 3435 C > T and risk of PD. The multivariate logistic regression model was used to evaluate the effects of the covariates on the phenotypes. Haplotypes' frequencies were estimated using the Expectation-Maximization algorithm. The frequency of each individual SNPs; -41 A > G (intron -1), -145 C > G (exon 1), -129 T > C (exon 1), 1236 T > C (exon 12), 2677 G > T/A (exon 21), 3435 C > T (exon 26), and 4036 A > G (exon 28) did not differ between PD and controls. However, there was a trend towards significance in PD patients having the haplotype 2677G-3435C (p < 0.09, chi-square 2.85, odds ratio 0.25, 95% CI 0.06-1.08). Haplotype constructs of the other loci did not differ significantly between the two groups. There was a weak protective effect of the haplotype 2677G-3435C in our white population. However, the MDR1 haplotypes did not generally modulate the risk of PD.

Entities:  

Mesh:

Year:  2004        PMID: 15542248     DOI: 10.1016/j.neulet.2004.09.046

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  P-Glycoprotein Transport of Neurotoxic Pesticides.

Authors:  Sarah E Lacher; Kasse Skagen; Joachim Veit; Rachel Dalton; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

Review 2.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

3.  MDR1 variants and risk of Parkinson disease. Association with pesticide exposure?

Authors:  Katja Zschiedrich; Inke R König; Norbert Brüggemann; Norman Kock; Meike Kasten; Klaus L Leenders; Vladimir Kostić; Peter Vieregge; Andreas Ziegler; Christine Klein; Katja Lohmann
Journal:  J Neurol       Date:  2009-01-29       Impact factor: 4.849

4.  Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.

Authors:  Sarah E Lacher; Julia N Gremaud; Kasse Skagen; Emily Steed; Rachel Dalton; Kent D Sugden; Fernando Cardozo-Pelaez; Catherine M T Sherwin; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2013-12-02       Impact factor: 4.030

5.  ABCB1 single nucleotide polymorphisms in the Brazilian population.

Authors:  Marcos Antonio Mauricio Scheiner; Arthur Motta Damasceno; Raquel Ciuvalschi Maia
Journal:  Mol Biol Rep       Date:  2009-05-13       Impact factor: 2.316

6.  Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's disease.

Authors:  Shilpa Narayan; Janet S Sinsheimer; Kimberly C Paul; Zeyan Liew; Myles Cockburn; Jeff M Bronstein; Beate Ritz
Journal:  Environ Res       Date:  2015-10-19       Impact factor: 6.498

7.  Genetic association of NOS1 exon18, NOS1 exon29, ABCB1 1236C/T, and ABCB1 3435C/T polymorphisms with the risk of Parkinson's disease: A meta-analysis.

Authors:  Hongbin Huang; Cong Peng; Yong Liu; Xu Liu; Qicong Chen; Zunnan Huang
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 8.  Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP.

Authors:  Mariline Gameiro; Renata Silva; Carolina Rocha-Pereira; Helena Carmo; Félix Carvalho; Maria de Lourdes Bastos; Fernando Remião
Journal:  Molecules       Date:  2017-04-08       Impact factor: 4.411

9.  Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA.

Authors:  A L Bartels; A T M Willemsen; R Kortekaas; B M de Jong; R de Vries; O de Klerk; J C H van Oostrom; A Portman; K L Leenders
Journal:  J Neural Transm (Vienna)       Date:  2008-02-12       Impact factor: 3.575

10.  Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.

Authors:  Marek Droździk; Monika Białecka; Mateusz Kurzawski
Journal:  Curr Genomics       Date:  2013-12       Impact factor: 2.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.